Aclaris Therapeutics Inc

ACRS · NASDAQ

Pharmaceutical Preparation Manufacturing

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

ESG Scores

Overall ESG

8.4

Environmental

4.5

Social

5.8

Governance

5.7

Public ESG Grades

Overall: B (Medium)

E: BS: BG: B

Gender Diversity

Female Directors0.1%

Female Executives0.05%

CEO GenderMale

Market Data

Price$3.48+0.20 (+6.10%)

Market Cap$483M

P/E Ratio—

EPS$—

52W High$6.60

52W Low$1.88

Beta0.94